Nownews財經新聞: 生達、大日本住友合作 抗精神病藥物在台申請許可

Nownews財經新聞 www.nownews.com

Earn an MBA degree Advance your career with an MBA Only $325 per credit hour From our sponsors

生達、大日本住友合作　抗精神病藥物在台申請許可 Oct 29th 2013, 05:04 〔記者楊伶雯╱台北報導〕大日本住友製藥（Dainippon Sumitomo Pharma Co., Ltd.，簡稱「DSP」）與生達簽訂授權合作協議，將由生達獨家取得第二代抗精神病藥物（lurasidone）產品在台銷售權利，已正式向台灣衛生福利部食品藥物管理署提出治療精神分裂適應症的申請，這次送件也是lurasidone在亞洲地區首件許可申請。

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions